everything-possible-shutterstock-com-2

everything possible / Shutterstock.com

14 April 2016Americas

Regeneron agrees CRISPR/Cas licensing deal

Regeneron Pharmaceuticals has agreed a licensing deal that it says will enable it to advance CRISPR/Cas gene-editing technology.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Let CRISPR/Cas9 battle commence

11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

CRISPR: careless talk costs patents

29 October 2015 Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports.

More on this story

Let CRISPR/Cas9 battle commence

11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

CRISPR: careless talk costs patents

29 October 2015 Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports.

More on this story

Let CRISPR/Cas9 battle commence

11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

CRISPR: careless talk costs patents

29 October 2015 Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’

Powell Gilbert launches Düsseldorf office with leading patent litigator

Startups toolkit: Why investors want more than patents

J&J fends off generic schizophrenia drug bids

Kilpatrick adds ‘seasoned litigator’ as trademark partner

WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond

Startup challenges rival over brain monitoring tech at ITC

UKIPO rejects Boehringer’s SPC for horse inhaler